Author Archives: admin


Over 2,000 patients get stem cell treatment for COVID-19 in UAE | MEO – Middle East Online

ABU DHABI - The Abu Dhabi Stem Cell Centre (ADSCC) has treated more than 2,000 patients suffering from COVID-19, with 1200 already fully recovered from the effects of the virus, according to state news media agency WAM.

ADSCC announced that it had succeeded in ramping up the number of treatments from the 73 in the initial clinical trial.

The large increase was due to a major effort by staff at the centre to treat as many people as possible following the UAE governments decision to make it available free of charge to all moderate-to-high risk COVID-19 patients in the Gulf state.

The Governments decision came after the treatment, which is branded UAECell19, showed efficacy and an impressive safety profile reflected in the absence of significant changes in adverse events reported, an absence of any unexpected serious reactions (such as anaphylaxis, allergic reactions or sudden death) and an absence of any lung complications as determined by radiological exams from inhalation of the nebulized product.

A team of doctors and researchers at ADSCC, led by Dr Yendry Ventura, announced in May they had developed a new treatment for COVID-19 patients.

UAECell19, an autologous stem cells based therapy, appears to help the body fight the virus and makes the disease less harmful.

Following an initial trial, researchers were able to conclude that UAECell19 reduced the duration of hospitalization from 22 days to just six, when compared to patients who had received standard treatment.

Further analyses revealed that patients treated with the stem cells were 3.1 times more likely to recover in less than seven days than those treated with standard therapy, and 67% of the patients who received the stem cells treatment owed this recovery to the new treatment.

ADSCC has since secured intellectual property rights protection for UAECell19, which opens the way for the treatment to be shared widely so more patients can benefit.

ADSCC said researchers were at various stages of several investigatory efforts to establish effectiveness (Phase 3 trial), optimal efficacy of dosage, and efficacy to treat other respiratory diseases such asthma, COPD, and cystic fibrosis.

Read more here:
Over 2,000 patients get stem cell treatment for COVID-19 in UAE | MEO - Middle East Online

Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore – Yahoo Finance UK

A six-year-old who won the nations hearts in his battle with leukaemia has been given a heroes welcome after flying home following months of life-saving cancer treatment in Singapore.

Brave Oscar Saxelby-Lee from St Johns, Worcester, was diagnosed with an aggressive blood cancer in December 2018 after his parents noticed unusual bruising on his legs.

Doctors gave him months to find a stem cell match to save his life which led to parents Olivia Saxelby, 25, and Jamie Lee, 28, launching a UK-wide appeal for donors.

Last March a record-breaking 4,855 volunteers queued in the freezing rain after Oscars primary school in opened as a testing centre.

In total more than 10,000 people were tested across the UK until a match was finally found.

Read more: Mum-to-be plagued by headaches diagnosed with incurable brain tumour

But just months later, the family faced further anguish after discovering Oscars cancer had returned.

After a crowdfunding campaign raised 600,000, Oscar was flown to Singapore for pioneering treatment not available on the NHS.

Oscar became only the second child in the world to undergo CAR-T therapy before having a second bone marrow transplant using stem cells from dad Jamie.

Oscar Saxelby-Lee, with his mum and dad during his time having treatment in Singapore. (SWNS)

Just three months after the successful operation, Oscar and his parents were given the all clear to return to the UK and hours after touching down he was driven see his classmates, who cheered as he drove past the school gates.

In heartwarming pictures Oscar grins from ear to ear as his proud dad sits next to him and his mum breaks down in tears of joy.

Pupils gave Oscar a huge bunch of colourful balloons which the youngster struggled to fit inside the car.

Read more:Woman diagnosed with cancer 48 hours before giving birth

Jen Kelly, from the Grace Kelly Trust which helped raise 173,000 to fund his life-saving treatment, said: The Grave Kelly Trust is delighted to see Oscar returning home to the UK with his mum and dad.

Out smiles have been growing ever wider as we watched Oscars miraculous journey.

We are so proud to have been able to play a key part in Oscars bid for life-saving treatment in Singapore and it is wonderful to see Oscar doing so well following his ground-breaking treatment.

This news is amazing, not just for Oscar, but potentially for other children in a similar position in the future.

Oscar still has a way to go and will need to be shielded for a good while longer once he gets home, but he remains cancer free and smiling.

Read more:Parents spot cancer in babys eye after photo taken

Oscar leaves Hospital in Singapore. (SWNS)

Story continues

Throughout his treatment, Oscar has kept in touch with his classmates and teachers from his hospital bed via an innovative robot - nicknamed Ozzybot.

His headteacher Kate Wilcock, who organised the huge donor registration event and Ozzybot lessons, said: There have been plenty of ups and downs to get here but this is the absolute icing on the cake that hes come home, cancer free and its worked.

Our future plans now will be to support Oscar and his family and even start some learning at home.

Then we will be working really closely with Olivia, Jamie and Oscar for some transition into school.

That will be the best day when he walks back through the door at Pitmaston Primary.

Oscar made a surprise visit to his classmates on his return from Singapore. (SWNS)

When he left hospital for the final time in Singapore Ozzy, as he is affectionately nicknamed, was given a guard of honour by medical staff.

A video posted on the Hand in Hand for Oscar Facebook page, shows the youngster beaming as he is driven away and shouts: Bye hospital, thank you!

Read more: Six-year-old runs marathon for the NHS dressed as his favourite super-heroes

His thrilled mum Olivia wrote: Cant quite believe it, crying bucket loads! The day weve dreamt of has now become a reality!

Were actually bringing him home!!!

You are our HERO Ozzy Bear, you truly truly are the most amazing miracle.

Enjoy every last minute of this journey darling, because YOU have owned [sic] it!

Additional reporting SWNS.

Follow this link:
Six-year-old given heroes welcome by his classmates after months of life-saving cancer treatment in Singapore - Yahoo Finance UK

BLM in STEM: We can’t forget that scientific research is steeped in colonialism – Varsity Online

Black Lives Matter

Sona Popat explores the historical relationships of Black people with scientific research and argues, along with Tedros Ghebreyesus, that the hangover from a colonial mentality has got to stop.

Content note: discussion of race and racism.

In the conversations about decolonising education, STEM subjects are often overlooked, perhaps because people consider them to be based on facts rather than perspectives. But when lecturers still often celebrate Watson and Crick for discovering the structure of DNA with no mention of Watsons racist views and support of eugenics it is clear that decolonisation of the sciences is important. Decolonisation is more than just becoming aware of the contributions of minority ethnic scientists, who have been forgotten and looked over when handing out Nobel Prizes and other awards. It is also acknowledging the history of science, which has exploited the bodies of ethnic minorities, particularly Black people, for use in research for the progression of scientific knowledge.

Henrietta Lacks

One of the best-known examples of Black people being exploited in science is Henrietta Lacks. A Black woman being treated for cervical cancer, doctors found that the cancerous cells taken from her behaved abnormally: they cycled at a high rate and had a long life-span, so were known as immortal. Until then, Dr George Otto Gey, the first researcher to study Lacks cells, had struggled with research into cancer cells because they had such a short lifespan, so very little testing could be done. The sample taken from Lacks before her death in 1951 was used to produce many more cancer cells, and this line of cells was named HeLa, after the first two letters of each of her names. These cells were taken without consent, as was considered to be standard practice at the time, and Lacks family did not find out about their continued use in research until many years later, in 1975, when other members of the scientific community contacted her family requesting blood samples and other materials to continue their research with. In fact, the HeLa cell line is still used for scientific research today, with over 60,000 scientific articles published based on research using HeLa cells. The story of Henrietta Lacks raises important questions of informed consent and ethics within science: HeLa cells have been influential in creating the polio vaccine and developing anti-cancer drugs such as tamoxifen, but their commercial use meant her cells were sold across the world by pharmaceutical companies for thousands of pounds whilst the Lacks family could not afford healthcare.

Two French doctors speaking on live television suggested testing COVID-19 vaccines in Africa.

James Marion Sims

James Marion Sims is considered to be the father of gynaecology for the contributions of his research to understanding the anatomy of the vagina and developing techniques that became the basis of modern vaginal surgery. His research in treating vesicovaginal fistula between 1845 and 1849 was based on experimental surgeries on Black slave women without anaesthesia; once successful methods were developed, he then treated white women with the condition. Although under modern-day ethics these actions are unacceptable, some people, such as L. Lewis Wall, continue to defend his methods because they conformed to standard medical practices at the time and have improved the quality of life of many women since then. Until April 2018, a statue of him stood in New York, removed only after people learned the true circumstances of his work and campaigned for its removal. Several medical terms and tools, such as the Sims position and Sims speculum, are still named after him. It seems that Sims is still celebrated, whilst the names and lives of most of the slave women he experimented on are lost to history.

The Tuskegee Syphilis Experiment

The Tuskegee Syphilis Experiment aimed to study the progression of untreated syphilis and determine whether there were racial differences in symptoms and outcomes of the disease. Between 1932 and 1972, nearly 400 Black men with syphilis thought they were receiving medical treatment, but in fact were only given a placebo. The trial continued even when penicillin, a successful treatment for syphilis, was developed and became widely available in 1947, and when the Public Health Service published updated guidelines on the use of human subjects in experiments in 1966. The catastrophic effects of this experiment included 128 of the men in the experiment dying due to syphilis or related complications, syphilis being spread to others, and 19 of their children being born with congenital syphilis. In 1972, the trial came to end when information about it was leaked to the press. This trial violated many ethical standards and damaged the trust of Black communities towards public health efforts and medical trials; a study suggests that the distrust has led to Black people, especially those from poorer economic backgrounds, being less likely to seek preventative healthcare, promoting racial inequalities in life expectancy.

READ MORE

The troubling return of scientific racism

COVID-19 and the future

Despite laws on ethics in research being put into place, the mentalities that drove this research still pervade today. An example of this is when two French doctors speaking on live television suggested testing COVID-19 vaccines in Africa, where [there] are no masks, no treatment, no intensive care services, although at the time African countries had very few cases compared to European countries. There would be no benefit in testing COVID-19 vaccines or drugs on people who are not suffering from it, so this statement was interpreted by viewers as having racial biases fuelling it. Professor Malegapuru Makgoba, an immunologist and South African National Health Ombudsman, said: It would be unethical to conduct a clinical trial where there is no disease or there is nothing to test for You [should] only conduct clinical trials when you have a disease, and its prevalence is enough for it to achieve scientific validity.

In response to the words of the French doctors, Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organisation said, the hangover from a colonial mentality has to stop. With criticism of a colonial mentality continuing to pervade in education, it is clear that celebrating the achievements of some scientists from minority ethnic backgrounds is not enough to call science decolonised. Instead, it is the responsibility of educational and research institutions to ensure that scientists and academics are aware of the exploitative history of science, and can learn from this knowledge to ensure that biases or breaches of ethics that have consistently disadvantaged Black people are not allowed to continue in scientific research in the future.

If you have been affected by any of the issues raised in this article, the following information and support is available:

Varsity is the independent newspaper for the University of Cambridge, established in its current form in 1947. In order to maintain our editorial independence, our newspaper and news website receives no funding from the University of Cambridge or its constituent Colleges.

We are therefore almost entirely reliant on advertising for funding, and during this unprecedented global crisis, we have a tough few weeks and months ahead.

In spite of this situation, we are going to look at inventive ways to look at serving our readership with digital content for the time being.

Therefore we are asking our readers, if they wish, to make a donation from as little as 1, to help with our running cost at least until we hopefully return to print on 2nd October 2020.

Many thanks, all of us here at Varsity would like to wish you, your friends, families and all of your loved ones a safe and healthy few months ahead.

Here is the original post:
BLM in STEM: We can't forget that scientific research is steeped in colonialism - Varsity Online

Exporting the Virus – The Investigative Fund

Jude said his body ached, and he was feverish. The 40-year-old was being held with dozens of other Haitians in a crowded U.S. Immigration and Customs Enforcement facility at the Alexandria International Airport in Louisiana. They give you Tylenol, ibuprofen, thats it, he told The Intercept in late May. After that, they just want to send you right back to your country. If you die, you die.

Jude, who is being identified by a pseudonym to protect him and his family, said hed tested positive for the coronavirus at the nearby Pine Prairie ICE Processing Center, where hed begged staff to send him to the hospital. But instead of receiving medical treatment, Jude said, he was being deported back to Haiti.

With approximately 120 ICU beds, and even fewer ventilators, for a population of 11 million, the island nation was bracing for the worst. Haiti had already closed its borders and shut down airports in March, after its first two cases of infection were reported, and medical experts warned the pandemic could be catastrophic for the impoverished countrys already debilitated health system. But the morning after he spoke with The Intercept, Jude was fitted with shackles on his wrists and ankles and marched out to a chartered plane waiting on the runway. With him were four other Haitian immigrants who told The Intercept that they had also been quarantined at Pine Prairie after testing positive for the virus. The May 26 deportation flight was one of seven to touch down in the Haitian capital since President Donald Trump declared the pandemic a national emergency on March 13.

As countries closed their borders and public health guidance urged restrictions on movement to contain the pandemic, the United States likely charteredmore than 350 deportation flights to at least 15 countries in Latin America and the Caribbean between February and late June, according toflight dataanalyzed by the nonprofit Center for Economic and Policy Research. Some of those flights had people on board who tested positive for the coronavirus after landing, according to government officials in the receiving countries. CEPRsanalysis, based on data from the public flight tracker FlightAware, designated flights as likely deportations if they were operated by airlines known to charter with ICE and matched known deportation routes. The true number of deportation flights is probably even greater, according to CEPR.

New cases of the coronavirus are rapidly rising in most of Latin America. Some government officials complain that instead of helping the region fight the pandemic, the U.S. is only fanning the flames of contagion. Interviews with people detained by ICE and government and public health officials in Haiti and Guatemala make clear the repercussions of hard-line immigration enforcement at any cost. Most imminent are the public health concerns, as the U.S. fails to consistently test for Covid-19 infections among those it plans to deport. Beyond that, reporting in receiving countries reveals that returning migrants have become targets for blame, while limited public health systems struggle to cope with the crisis. Finally, there are growing diplomatic consequences, as the U.S. pushes allied nations to allow the deportation flights to land.

In response, leaders like Haitian Foreign Affairs Minister Claude Joseph have repeatedly pleaded with the U.S. government to suspend the flights. I have many times over the phone tried to convince our American friends, Josephtold the Miami Herald. U.S. Congress members and medical organizations have also petitioned the Trump administration to issue a moratorium, with groups like Doctors Without Borders warning that a major outbreak will be catastrophic for countries with fragile healthsystems. But while the Trump administration has invoked the pandemic to justify newrestrictionson immigration, it has continued to forge ahead with deportations, creating a petri dish for the virus in crowded immigration detention facilities and then exporting it overseas.

From the early days of the pandemic, the U.S. paid little heed to public health guidance when it came to detained immigrants, and detention centers have becomehot spotsfor the illness. ICE updates its numbersirregularly, but as of June 19, it had tested 8,858 detainees; as of June 25, 2,521 were reported positive for the virus. An epidemiological model, funded by the National Institute of General Medical Sciences, estimated from ICEs existing data that at least 72 percent of the population in detention could potentially becomeinfected. Yet ICE has continued to detain immigrants, then deport them, and has even recently expanded its flights to include Liberia and India, where health officials confirmed that22 peoplehad tested positive for Covid-19 after landing on May 19.

Central Americas Northern Triangle, however, has received the majority of flights, since many of the migrants arriving at the U.S.s southern border in recent years have been from El Salvador, Honduras, and Guatemala. Of 351 likely deportation flights between February 3 and June 24, according to CEPR, 240 went to the Northern Triangle. Guatemala was the top recipient with 100 flights.

After dozens of returnees tested positive in March and April, Guatemala refused to accept any more flights until the U.S. agreed to certify that each person had tested negative before departure. After the U.S. agreed, flights resumed in May, but shortly thereafter, another person tested positive afterlandingin Guatemala City, casting doubt on the reliability of that testing. ICE did not respond to The Intercepts repeated requests for information on testing, including its testing protocol agreement with Guatemala.

Graphic: Soohee Cho/The Intercept. Source: Center for Economic and Policy Research

Central Americas Northern Triangle received the majority of the 351 likely ICE deportation flights identified by the Center for Economic and Policy Research between February 3 and June 24. The drought-wracked region is now grappling with a rise in new coronavirus cases.

The countrys new president, Alejandro Giammattei, a physician and conservative, was notably livid during a May 21 online event hosted by the Atlantic Council. The previous month, Guatemalas public health ministry hadreportedthat nearly 20 percent of the countrys Covid-19 cases had come from U.S. deportation flights. Our hospitals have limited capacity, but now we have to treat these patients infected with a disease that didnt originate here, he said. This creates such a burden for us. Guatemala is an ally of the United States, but I dont believe the U.S. is an ally to Guatemala, because they dont treat us like one.

Theyre capturing migrants in the United States, then putting them in detention where they get infected, and sending them back to us, said Dr. Lucrecia Hernndez Mack, a physician and member of the Guatemalan Congress. And our hospitals can barely cope from day to day, let alone with the situation we are in now.

ICEclaimsthat it follows the Centers for Disease Control and Preventions guidelines to prevent the spread of Covid-19. Yet while the CDC has emphasized the need for social distancing and warned that any form of travel risks spreading the virus, Jude said he was transferred to multiple detention centers in March and early April, traveling hundreds of miles on crowded buses before testing positive later that month. Even after he tested positive, he said, ICE kept putting him on buses with other detainees rather than isolating him until he recovered.

In March, Jude was shuffledtovariousfacilities in Georgia, including the Irwin County Detention Center, the Folkston ICE Processing Center, and the Stewart Detention Center. From there, Jude said, he was placed on a packed bus with others from Haiti, Guatemala, and Mexico and sent to an ICE staging facility at the Alexandria airport in Louisiana to await deportation.

Jonathan Wiggs via Getty Images

The Stewart Detention Center in Lumpkin, GA.

At the airport, he was held in a room with about 60 other Haitian immigrants. Among them was Stanley, 25, who like other detained or recently deported immigrants cited in this article is being identified by a pseudonym. Stanley told The Intercept that hed been transferred from the Glades County Detention Center in Florida, where he said several detainees were sick with fevers and having difficulty breathing. Sixty-six detainees at Glades have since tested positive for Covid-19,according to ICE.

On April 7, after nearly a week at the airport, Jude and Stanley said they were preparing to be deported to Port-au-Prince when they were pulled from the flight at the last minute, along with about two dozen other Haitians. At least three individuals who remained on the flight tested positive for Covid-19 after landing in Haiti, according to the countrys Ministry of Public Health. A week after the flight,13 staff membersat the Alexandria facility also tested positive for the virus.

Jude and Stanley were transferred to the nearby Pine Prairie ICE Processing Center, where according to Stanley, they were put in a cell with others whod been detained with them at the airport. Jude, Stanley, and four of their cellmates told The Intercept that they came down with fevers and body aches soon afterward. One man, 34-year-old Daniel, said he was so sick he couldnt walk. I couldnt even move, he said. I had to get wheelchaired to a vehicle and wheelchaired to the hospital. All six men said they tested positive for the virus at Pine Prairie in April. ICE has reported 30 confirmed cases at the facility.

GEO Group, the private prison company that runs both the Alexandria and Pine Prairie facilities, declined to comment for this article. ICE did not respond to The Intercepts requests for comment, nor did the Glades County Detention Center.

Henry Lucero, the executive associate director of ICEs Enforcement and Removal Operations,tolda Senate Judiciary Committeepanelin June that due to a lack of testing kits, ICE doesnt always test people before moving them from one detention facility to another, nor does it test everyone it returns on deportation flights. Lucero said the agency had acquired 2,000 testing kits from the Department of Health and Human Services and is slated to receive an additional 2,000 tests per month from HHS for the foreseeable future. HHS did not respond to repeated requests from The Intercept for information about the shortage of tests.

With limited testing, the agency cant accurately gauge how extensively the virus has spread among detainees, said Dr. Joseph Shin, co-medical director of the Weill Cornell Center for Human Rights in New York. Its like rolling the dice, he said. They may not be symptomatic, but you dont know if they are infected, or that theyre going to be symptomatic and theyre just in an incubation period. Also problematic is the decision to blindly move detainees multiple times. It flies in the face of our general principles of social distancing and minimizing the movement of people, Shin said. Weve seen how quickly this virus can leap to individuals in congregate settings, and that includes the staff, and also can follow these people out into the community to seed further infections.

During his testimony, Lucero conceded that his agency knew some deportees had tested positive after arriving in their home countries on U.S. flights. We are aware of reports, he testified. But there were no known positives that were removed actively with Covid-19. Before someone boards a flight, agents look for symptoms such as cough or fever, Lucero said, adding that they also randomly test a subset of detainees regardless of their symptoms.

In negotiations with U.S. diplomatic staff, governments like Haitis have received additional assurances. The American government assured the Haitian government that the people who would be deported in the month of May had not been exposed to the virus, a spokesperson for Haitis foreign ministry told The Intercept. The U.S. Embassy in Haiti declined to comment.

Because of the high risk at sites like detention centers, the United Nations hasrecommendedthat individuals who test positive for Covid-19 in such facilities be quarantined in isolation from the general population until they have tested negative on two subsequent tests. Jude, Stanley, and Daniel said the medical staff at Pine Prairie initially told them that they would not be removed from quarantine until they had tested negative twice. Stanley said they were tested regularly using a cotton swab inserted deep into their nasal cavities. The tests caused so much pain and discomfort that some of the detainees began to object. Every 24 hours, they kept coming to pressure us to take the test, said Stanley. They just come every day saying, OK, you guys gotta take a test.

Altogether, Jude said he was tested six times at Pine Prairie. Each time, he was told the results were still positive, he said. But just a day after he received the results of his sixth test, Jude said staff told him to pack up because ICE planned to deport him the next morning. He was listed as a passenger on aMay 11 flightto Port-au-Prince, according to a flight manifest obtained by The Intercept.

Once again, Jude and Stanley were transported to ICEs holding facility at the Alexandria airport. We were shackled up, said Stanley. With everybody else, to get ready for the flight.

But, after public outcry, the two men were pulled from the flight a second time. Prior to their departure, another detainee, Stephane Etienne, had spoken to immigration advocates andthe mediaabout his own recent positive test results. He said he knew of others on the flight manifest who had also tested positive.

The men gained only a short reprieve. Two weeks later, Jude, Stanley, and Daniel were all deported. Two other Haitian immigrants who told The Intercept that they had tested positive at Pine Prairie were deported as well. Jude said he was still reporting symptoms of Covid-19 at the time. As the Miami Heraldreported, immigrant rights advocates said they knew of eight Haitians deported on May 26 who had previously tested positive. Yet Daniel told The Intercept that there were actually nine of them on the plane that he knew of who had been in quarantine after testing positive at Pine Prairie.

When the buses arrived at the airport, Jude and Daniel said they each once again had a swab jabbed up their noses. This time, they were given a rapid test, according to interviews and theMiami Herald. As Lucero mentioned during his testimony, ICE had recently bought 10 Covid-19 rapid-testing machines manufactured by Abbott Laboratories, which Trump has touted in press briefings. The Abbott ID NOW test, run on a machine about the size of a toaster, typically produces a result within 15 minutes. The machines are currently being used under an emergency authorization issued by the government, but the tests accuracy is still being questioned by the U.S. Food and Drug Administration. In May, the FDA issued anadvisorywarning that the rapid test could yield potential inaccurate results. The FDA stated that it is working with Abbott to alert the public that any negative test results that are not consistent with a patients clinical signs and symptoms should be confirmed with another test.

After testing negative with the rapid test, Jude and Daniel said they were told that theyd been cleared to travel. They were among 30 Haitians ICE deported on May 26. As the Department of Homeland Security lateracknowledged, only 16 of these deportees were even given a rapid test for Covid-19 before they were deported.

Returning migrants not only suffer from the physical effects of the virus but also become targets for blame in their home countries.

At La Aurora International Airport in Guatemala City, where deportation flights land, officials dont have enough tests to be able to test each returning migrant. Instead they are checked for any visible signs of illness such as fever and cough, said Hernndez Mack, who has been monitoring the governments response to the pandemic. They take their temperature and give them a quick physical evaluation, she said.

Photo by JOHAN ORDONEZ/AFP via Getty Images

An immigration official uses a protective face mask as a preventive measure against the new coronavirus, COVID-19, upon the arrival of Guatemalan migrants deported from the United States, at the Air Force base in Guatemala City, on March 12, 2020.

Initially, in March, deportees were sent to a cordoned-off wing of the airport, where a few bare mattresses lay on the floor, and there was little access to food or water, according to Hernndez Mack and local news reports. The conditions were so dismal that many walked out, taking a bus or hitching rides home, inadvertently infecting relatives and others along the way.

By June 25, Guatemala had 14,819 confirmed cases and 601 deaths, but the real toll is likely much higher, said Hernndez Mack, who is also Guatemalas former minister of public health. Infections are being spurred even higher by Mexico deporting thousands more people over its southern border with Guatemala. No one is receiving them or evaluating them, Hernndez Mack said. They dont get the test, so we dont know if they are positive, and they are returning to their communities not knowing they are contagious and could infect their families. We have a very precarious health system, which is starting to collapse. Doctors and nurses have protested conditions, according to local newsreports, demanding more protective gear and equipment, and the director of the nations primary hospital treating coronavirus patients recently tested positive.

To address the growing need, Hernndez Mack said the government has created a makeshift hospital in an industrial park in Guatemala City where returning migrants with mild symptoms are now quarantined. The more serious cases are sent to a hospital in the city, but as of mid-May, it had already been overwhelmed, she said.

Much of Guatemala is rural and mountainous, with few health services and largely cut off from the nations wealthier capital. In some communities, recently deported migrants are being singled out. Since March, Giammatteis administration haspublicizedthe idea that migrants are bringing Covid-19 with them from the U.S., while at the same time, his administration hasfailedto create an effective educational campaign about how people can prevent the spread of the virus. Both elements of that approach have helped sow panic and the persecution of returning migrants, Hernndez Mack said. There are communities who have rejected them not knowing whether they are infected or not, she said. They dont let them enter or reunite with their families, because of the stigma.

Buses carrying migrants have been barred from entering towns, and some returnees have been expelled from their communities because of fear of contagion. InEscuintla, on the southern coast of Guatemala, one familys home was surrounded by a mob of angry neighbors who demanded that they leave after one of them tested positive for the virus and the family was placed under quarantine, said Renzo Rosal, a political analyst in Guatemala City. The police arrived and barely saved them, he said. People are scared.

Exporting the virus to the very allies the United States needs to curb immigration to its southern border is fostering resentment as these leaders are forced to beg State Department and Homeland Security officials not to send their citizens back if they are sick.

In Haiti, calls for a ban on flights increased in April, when three Haitians tested positive for Covid-19 after disembarking in the Haitian capital. In an open letter to Haitian President Jovenel Mose, 14 civil society groups urged his government to negotiate a moratorium suspending all deportations from the U.S. during the pandemic. A committee of leading Haitian doctors and scientists alsorecommendeda moratorium. Guatemala has gone a step further, repeatedly suspending the flights only to lift the moratoriums under pressure from the United States.

Before and during the pandemic, Trump administration officials have threatened that any country that refuses to accept the deportation flights could face consequences, including trade tariffs and hits to visas and humanitarian aid. In late March, a senior DHS official speaking on backgroundtoldreporters in a teleconference that it was not an acceptable position to the government of the United States that any country in the world whose citizens illegally entered our country would not take those citizens back under virtually any circumstances. The official added, Theres simply no defense of that position, and we feel very, very strongly about that, and we intend to act accordingly if the needs arise in the future.

For Haiti and others dependent on U.S. foreign aid, Guatemala has served as a cautionary example. The country was the first to demand that the U.S. no longer return deportees who were positive for Covid-19, while neighboring El Salvador and Honduras have allowed the deportations to continue and been largely compliant. In April, Guatemala was conspicuously absent from any mention as TrumppraisedHonduras and El Salvador for their help in curbing migration, saying that the U.S. would be sending both countries desperately needed ventilators. Guatemala didnt fail to notice the slight. Weve seen how theyve assisted other countries with ventilators, Giammatteisaidduring his Atlantic Council appearance. We dont feel very grateful for the way we have beentreated.

At least one U.S. official denied that Guatemala was suffering reprisals for being the first to publicly protest the flights. State Department official Michael Kozak said during a teleconference call that there wasnt any hard linkage between cooperation on removals and ventilators. Its not that we havent had a cooperative relationship with them, he said of Guatemala. Its just theyve run into some snags and were working through that withthem.

But the perception from within the country is otherwise, said a retired Guatemalan diplomat, who asked to remain anonymous because hes not authorized to speak for the current government. It is my understanding that we are being punished, he said. The administration has already said it would withhold visas for Guatemalan citizens, including businesspeople and government officials, so its a serious challenge for a country like Guatemala that is close to the U.S., and its a threat that is taken seriously.

SinceJude was deported, cases in Haiti have more than quadrupled, from less than 1,100 in late May to more than 5,400. A Haitian civil servant involved in the countrys Covid-19 response efforts, who did not wish to be identified because he fears reprisals, told The Intercept that he fears that were sitting on a ticking time bomb. The pandemic is hitting at the same time as a deepening political and economic crisis, and the head of the Pan American Health Organization recently warned that there is real danger of a large-scale outbreak followed by a humanitarian crisis in Haiti.

Deportations from the U.S. are exacerbating these issues. Honduras, which has received the second-highest number of flights after Guatemala, has confirmed more than 14,500 cases and 417 deaths, while in El Salvador, at least 5,300 cases and 126 deaths have been reported. Several likely deportation flights from the U.S. have also touched down in some of the hardest-hit countries, including Brazil, now second in the world for infections; Ecuador, which has one of the highest fatality rates in Latin America; and the Dominican Republic, which has more Covid-19 infections than any other Caribbean country.

The situation is also dire in Guatemala, where infections outpace neighboring El Salvador and Honduras. Paulina Lopes, a Mayan community health organizer in the city of Santa Cruz del Quiche in the western highlands, said many in Indigenous Mayan communities are not reporting to the authorities when theyre sick. Lopes said that shes also heard that some who are critically ill are dying at home because they fear having their community cordoned off by the military if an outbreak is reported. In much of rural Guatemala, hospitals are more like ill-equipped health centers, Lopes said, and dont have the equipment or capacity to receive people. Even when theres no pandemic, they still dont treat people.

A strict lockdown enforced by the military and police in Indigenous communities has also increased hunger and malnutrition, already a problem in the long-suffering region wracked by drought and climate change. They have locked us up in our homes, and there is no work, said Lopes. People cant go to their land to collect or cultivate their food. Since the lockdown began in mid-March, families suffering from hunger have descended from the mountains, waving white flags to signify that they are starving. They now line the streets of towns and the sides of highways asking for help. I have never seen something like this in my life, Lopes said. Every day it is very tense, very difficult.

Families cant afford food, let alone face masks or hand sanitizer, she said. It is a total lie that the government is helping the rural areas. They say theyve sent supplies, but its a lie. The help hasnt arrived in our communities.

Guatemala was already reeling after Trump cut foreign aid to the country in 2019, because he claimed that it wasnt doing enough to prevent migration to the United States. The rate of malnutrition in Indigenous communities is close to 65 percent. Programs run byMercy Corps, Save the Children, and other nonprofits that provided food assistance were discontinued due to lack of funding. A longtime U.S. congressional staffer who specializes in Latin American policy, who asked not to be named since he fears reprisal, said that aid to the Northern Triangle had been provided in a bipartisan manner for decades until the Trump administration ended it. Cutting foreign aid was an incredibly counterproductive move, because this funding was addressing the root causes of migration, he said. And stopping people from making the dangerous trek in the first place.

It would be difficult to find many in the State Department, he said, who thought cutting the funding was good policy. I mean, this is coming directly from the top, he said. This was, you know, a typical tweet by Trump and then the State Department has to go into full gear and figure out what to do next.

Even when Trump announced in October that he would restore some funding, the congressional aide said, much of it was to beearmarkedfor law enforcement rather than development and food security. They would argue that the security funding is needed to stem the migration, but I think thats ludicrous, he said. I mean its one piece of the puzzle, but if you dont have a food secure western highland region in Guatemala and people are starving, then theyre going to migrate. You need both pieces.

But migration trumps everything in this administration, he said, including growing concerns about leaders in the region exploiting the pandemic to consolidate power. The Trump administration has stood by without protest while President Bukele is becoming increasingly authoritarian, he said of El Salvadors new president, Nayib Bukele, who has given the police broad authority to use deadly force and arrest anyone violating quarantine. Bukele also ordered hundreds of prisoners stripped to their underwear and packed tightly together in a prison patio as a show of force against gang leaders. The U.S. administration didnt speak up either, he said, when Honduran President Juan Orlando Hernndez, who is being investigated for drug trafficking by the U.S. Justice Department, ended his countrys anti-corruption commission in January. And it remained silent last September when Guatemala dissolved its own U.N.-backed anti-corruption commission.

The only thing this administration cares about is, Are they taking our deportees? And will they work with us in enforcing draconian immigration policies? Anything else is irrelevant, he said.

Everything the administration is doing now, from cutting aid to deporting people infected with the coronavirus and paying no heed to growing corruption, will only further destabilize the region. You might not see it today because of the pandemic or because of current immigration policies, he said. But abandoning Central America will have long-term consequences. There will be more children, more families who are going to take the dangerous journey north.

Rosal, the political commentator from Guatemala City, said that ultimately his country, like so many others, believes that it has little choice but to acquiesce to the demands of its more powerful benefactor to the north. We can neither afford to accept the flights nor reject them, he said. Either way, we lose.

Research assistance by Akil Harris.

See the original post here:
Exporting the Virus - The Investigative Fund

Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute…

CRANFORD, N.J., June 26, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, announced today that the Company has received a written response from the U.S. Food and Drug Administration (FDA) in regards to its pre-investigational new drug (PIND) application for its induced mesenchymal stem cells (iMSCs) to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in patients with COVID-19.

The FDA acknowledged that the Company could apply for fast track designation and also provided Citius with the chemistry, manufacturing, and control (CMC) requirements for the proposed trials. The Company plans to initiate actions on the FDA's recommendations and follow up with the FDA with an Investigational New Drug (IND) application under the Coronavirus Treatment Acceleration Program (CTAP).

Myron Holubiak, Chief Executive Officer of Citius, commented, "We appreciate the FDA's thoughtful guidance on our unique, allogenic mesenchymal stem cells derived from induced pluripotent stem cells (iPSCs). We understand that iPSC-derived stem cells are not the same as adult-donor derived cells and, therefore, would require different proof of concept studies. Since we believe in the advantages of iPSC MSCs over donor-derived cells, we intend to develop assays recommended by the FDA and demonstrate the safety of these MSCs in our preclinical studies. We are committed to the successful completion of the required clinical trials to provide an effective and safe therapy for ARDS due to COVID-19."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visitwww.citiuspharma.com.

About Citius iMSCCitius's mesenchymal stem cell therapy product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary mRNA-based (non-viral) reprogramming process. The iMSCs produced from this clonal technique are differentiated from adult donor-derived MSCs (bone marrow, placenta, umbilical cord, adipose tissue, or dental pulp) by providing genetic homogeneity. In in-vitro studies, iMSCs exhibit superior potency and high cell viability. The iMSCs secrete immunomodulatory proteins that may reduce or prevent pulmonary symptoms associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from a master cell bank.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 would benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement for a potential ARDS therapy with Novellus, Inc. within the option period; the ability to access the FDA's CTAP program for our planned ARDS therapy; risks associated with developing our product candidates, including any licensed from Novellus, Inc., including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; our need for substantial additional funds; risks associated with conducting our Phase 3 trial for Mino-Lok, including completing patient enrollment, opening study sites and achieving the required number of catheter failure events; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks related to our growth strategy; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 [emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

See more here:
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute...

Cell Sorting Market 2020, Top Key Players, Trends, Size, Drivers, Policies, Applications And Competitive Landscape To 2027 – 3rd Watch News

The report offers key drivers that propel the growth in the global ## market. These insights help market players in devising strategies to gain market presence. The research also outlined the restraints of the market. Insights on opportunities are mentioned to assist market players in taking further steps by determining the potential in untapped regions.

What is Cell Sorting?

Cell sorting is a technique to purify cell populations based on the presence or absence of specific physical characteristics. Cell sorting allows the separation of cells based on their intra- or extracellular properties, including DNA, RNA, and protein interactions, size, and surface protein expression. This is a unique attribute of many stem cell populations, including hematopoietic, embryonic, and cancer stem cells.

Get Sample PDF Of Cell Sorting Market @

https://www.theinsightpartners.com/sample/TIPRE00010455/

The cell sorting market is driving due to the growing prevalence of chronic diseases and cancer and the increasing demand for cell therapies for the treatment of these diseases. However, the high cost of devices, stringent regulations, and lack of skilled personnel with sound technical know-how is likely to restraint the market growth during the forecast period. Moreover, the rise in government initiatives to enhance health care facilities, focus on research and increase in research funding contribute to the growth of the market for cell sorting.

Segmentation Analysis:

The cell sorting market is segmented on the basis of product, technology, application and end user. Based on technology, the market is segmented as fluorescence-based droplet cell sorting, magnetic-activated cell sorting (MACS), micro-electromechanical systems (MEMS) microfluidics. On the basis of product, the market is categorized as cell sorters, cell sorting reagents and consumables, cell sorting services. on the basis of application, the market is categorized as research, clinical. On the basis of end user, the market is categorized as research institutes, pharmaceutical and biotechnology companies, medical schools, hospitals and clinical testing laboratories.

Major Players Included in this report are as follows:

1.Becton, Dickinson and Company 2. Bio-Rad Laboratories 3. Danaher Corporation 4. Merck Millipore 5. pluriSelect Life Science UG & Co. KG 6. STEMCELL Technologies Inc. 7. Sysmex Partec GmbH 8. Terumo BCT, Inc. 9. Thermo Fisher Scientific 10. Union Biometrica, Inc

Cell Sorting Market: Regional analysis includes:

Cell Sorting Market: Competitive Landscape-

Analysts have thoroughly evaluated the competitive landscape in the Cell Sorting Market. The report includes the study of key players in the Cell Sorting Market. It also outlines the strategic initiatives companies have taken in recent years to keep pace with increasing competition. It also includes an assessment of the financial perspectives of these companies, their research and development plans, and their future business strategies.

Chapter Details of Cell Sorting Market:

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Read More About This Report Athttps://www.theinsightpartners.com/buy/TIPRE00010455/

Key Questions Answered:

About us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact us: Call: +1-646-491-9876 Email:[emailprotected]

Visit link:
Cell Sorting Market 2020, Top Key Players, Trends, Size, Drivers, Policies, Applications And Competitive Landscape To 2027 - 3rd Watch News

Insight on the Growth of Autologous Stem Cell Based Therapies Market Growth with Challenges, Standardization, Competitive Market Share and Top Players…

The Autologous Stem Cell Based Therapies Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Autologous Stem Cell Based Therapies market reports deliver insight and expert analysis into key consumer trends and behaviour in marketplace, in addition to an overview of the market data and key brands. Autologous Stem Cell Based Therapies market reports provides all data with easily digestible information to guide every businessmans future innovation and move business forward.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2278181&source=atm

The worldwide Autologous Stem Cell Based Therapies market is an enlarging field for top market players,

The key players covered in this study Regeneus Mesoblast Pluristem Therapeutics Inc U.S. STEM CELL, INC. Brainstorm Cell Therapeutics Tigenix Med cell Europe

Market segment by Type, the product can be split into Embryonic Stem Cell Resident Cardiac Stem Cells Umbilical Cord Blood Stem Cells

Market segment by Application, split into Neurodegenerative Disorders Autoimmune Diseases Cardiovascular Diseases

Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Autologous Stem Cell Based Therapies status, future forecast, growth opportunity, key market and key players. To present the Autologous Stem Cell Based Therapies development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Autologous Stem Cell Based Therapies are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2278181&source=atm

This Autologous Stem Cell Based Therapies report begins with a basic overview of the market. The analysis highlights the opportunity and Autologous Stem Cell Based Therapies industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Autologous Stem Cell Based Therapies insight regarding the things which are driving and affecting the earnings of the market. The Autologous Stem Cell Based Therapies report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2278181&licType=S&source=atm

Research objectives and Reason to procure this report:-

Finally, the global Autologous Stem Cell Based Therapies market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Autologous Stem Cell Based Therapies industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Go here to see the original:
Insight on the Growth of Autologous Stem Cell Based Therapies Market Growth with Challenges, Standardization, Competitive Market Share and Top Players...

How cancer cells resist radiotherapy – The Star Online

Cancer stem cells are a cell type that was previously little known, but are now a controversial topic widely discussed in current cancer research.

A popular research subject, stem cells are precursor cells for various body cell types.

They play an important role in embryonic development, as well as in tissue maintenance.

Many types of cancer also involve a type of cell that shares many properties with stem cells.

While regular stem cells are precursors of healthy body cells, cancer stem cells are precursors of different types of cancer cells.

Normal stem cells and cancer stem cells therefore have many common aspects that are of interest to researchers.

One important factor is that cancer stem cells are resistant to irradiation and prevent the effective treatment of many types of cancer.

Cancer stem cells are a very contentious issue, explains molecular biologist Frdric Santer from the Department of Urology at the Medical University of Innsbruck, Austria.

It is still unclear whether they originate from normal stem cells or from differentiated, degenerate cells that are regressing.

Such processes are difficult to detect in living organisms.

However, he points out that the similarity of their properties is undisputed, in particular, their resistance to therapy.

The latter is a problem because cancer stem cells that survive therapy are held responsible for the recurrence of cancer in cured individuals.

The resistance of stem cells can be explained by natural necessities.

A certain resistance to environmental influences such as chemicals is useful for them, he says.

Regular cells have mechanisms that trigger cell death when DNA (deoxyribonucleic acid) is damaged.

Stem cells, on the other hand, are designed to regenerate damaged tissue.

So it makes sense that they survive in situations where other cells die, he explains.

How they manage to do that has not, however, been sufficiently researched.

But that is enormously important for cancer therapy, emphasises Santer, for whom this information deficit was inspiration for his research project, funded by the Austrian Science Fund (FWF).

We wanted to look at what happens at the level of genes during radiotherapy.

Two problems discovered

In order to do that, Santers team used tissue samples from patients with prostate cancer.

Unless it is very advanced, the primary therapy for prostate cancer is the surgical removal of the prostate.

This meant that the researchers had direct access to cancer cells from patients.

After surgery, the removed tissue is routinely sent to the pathology department, where a report is drawn up. Only then can Santers team use it for research.

It is not easy to cultivate these cells in the laboratory, he explains.

The process is complex and we had to invest a lot of time before we were able to create optimum conditions for the actual experiment.

After successful cultivation, the cell samples were irradiated in line with a protocol for radiotherapy that patients receive.

Irradiation causes DNA damage. If this damage is too extensive to be corrected by repair mechanisms, the cell normally dies, he explains.

However, some cells survived the irradiation process.

These cells were subsequently compared with the original tissue.

The researchers were particularly interested in gene expression, which refers to the process by which genes are translated into protein structures.

In the process, the genetic code in the cell nucleus is read and converted into RNA (ribonucleic acid).

An analysis of this RNA provides information about the processes taking place in a cell.

We found that two important processes of the radio-resistant cells are weakened, Santer shares.

One is the production of proteins that are regulated by interferons, which is used by the immune system to fight viruses and cancer cells.

In the irradiated cells, the production of proteins in the interferon cell-signalling pathway was inhibited.

This effect was also recently confirmed by another international study on breast cancer stem cells.

Another disrupted process was the cell cycle arrest, which involves a mechanism that prevents cell division in the presence of damaged DNA.

This mechanism was disrupted as certain proteins required for the process were not produced in sufficient quantities.

This actually constitutes a malfunction, but it helps the cell to survive because it can continue to reproduce without constraint despite the DNA damage, he says.

Both effects are problematic because they promote the development of cancer.

However, the more detailed understanding of these effects can now serve as a starting point for new cancer therapies, according to Santer. FWF

See more here:
How cancer cells resist radiotherapy - The Star Online

2020 Exosome Technologies Market Report- Growth with Capricor, Codiak and Evox Therapeutics among Key Players – 3rd Watch News

The research reports on Exosome Technologies Market report gives detailed overview of factors that affect global business scope. Exosome Technologies Market report shows the latest market insights with upcoming trends and breakdowns of products and services. This report provides statistics on the market situation, size, regions and growth factors. Exosome Technologies Market report contains emerging players analyze data including competitive situations, sales, revenue and market share of top manufacturers.

Get FREE PDF Sample of the report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=1781607

Top Companies in this Report-

Capricor Therapeutics Evox Therapeutics Ltd ReNeuron Group Plc Stem Cell Medicine Ltd Tavec Inc. Codiak Biosciences Inc. Therapeutic Solutions International Inc. ArunA Biomedical Inc. Ciloa

and more

Single User License: US $ 2995

Table of Contents

1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7

2 Exosomes in Healthcare 8 2.1 Overview of Exosomes 8 2.2 Drug Delivery Systems 9 2.2.1 Modified Release Drug Delivery Systems 9 2.2.2 Targeted Drug Delivery Systems 10 2.2.3 Liposomes 12 2.2.4 Viruses 14 2.2.5 Exosomes 17 2.3 The Exosome Lifecycle 18 2.4 Exosomes in Biology 18 2.5 Exosomes in Medicine 19 2.5.1 Biomarkers 19 2.5.2 Vaccines 20 2.6 Exosomes as a Therapeutic Target 20 2.7 Exosomes as Drug Delivery Vehicles 21 2.8 Therapeutic Preparation of Exosomes 21 2.8.1 Isolation and Purification 22 2.8.2 Drug Loading 22 2.8.3 Characterization 23 2.8.4 Bioengineering 23 2.8.5 Biodistribution and In Vivo Studies 23 2.8.6 Advantages of Exosome Therapies 24 2.8.7 Disadvantages of Exosome Therapies 24 2.9 Exosomes in Therapeutic Research 25 2.9.1 Exosome Gene Therapies 25 2.9.2 Exosome in Stem Cell Therapy 26 2.10 Exosomes in Oncology 27 2.10.1 Immunotherapy 27 2.10.2 Gene Therapy 28 2.10.3 Drug Delivery 29 2.10.4 Biomarkers 30 2.11 Exosomes in CNS Disease 30 2.11.1 Tackling the Blood-Brain Barrier 30 2.11.2 Exosomes in CNS Drug Delivery 31 2.11.3 Gene Therapy 32 2.12 Exosomes in Other Diseases 33 2.12.1 Cardiovascular Disease 33 2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36 3.1 Overview 36 3.2 Exosome Pipeline by Stage of Development and Molecule Type 36 3.3 Pipeline by Molecular Target 37 3.4 Pipeline by Therapy Area and Indication 38 3.5 Pipeline Product Profiles 38 3.5.1 AB-126 ArunA Biomedical Inc. 38 3.5.2 ALX-029 and ALX-102 Alxerion Biotech 39 3.5.3 Biologics for Autism Stem Cell Medicine Ltd 39 3.5.4 Biologic for Breast Cancer Exovita Biosciences Inc. 39 3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis Regenasome Pty 39 3.5.6 Biologic for Lysosomal Storage Disorder Exerkine 39 3.5.7 Biologics for Prostate Cancer Cells for Cells 40 3.5.8 CAP-2003 Capricor Therapeutics Inc. 40 3.5.9 CAP-1002 Capricor Therapeutics Inc. 41 3.5.10 CIL-15001 and CIL-15002 Ciloa 42 3.5.11 ExoPr0 ReNeuron Group Plc 42 3.5.12 MVAX-001 MolecuVax Inc. 43 3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke Isfahan University of Medical Sciences 44 3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer Codiak BioSciences Inc. 44 3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology Evox Therapeutics Ltd 44 3.5.16 TVC-201 and TVC-300 Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48 4.1 Interventional Clinical Trials 48 4.1.1 Clinical Trials by Therapy Type 48 4.1.2 Clinical Trials by Therapy Area 49 4.1.3 Clinical Trials by Stage of Development 50 4.1.4 Clinical Trials by Start Date and Status 50 4.2 Observational Clinical Trials 51 4.2.1 Clinical Trials by Therapy Type 51 4.2.2 Clinical Trials by Therapy Area 51 4.2.3 Clinical Trials by Stage of Development 52 4.2.4 Clinical Trials by Start Date and Status 53 4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67 5.1 Company Profiles 67 5.1.1 Capricor Therapeutics Inc. 67 5.1.2 Evox Therapeutics Ltd 72 5.1.3 ReNeuron Group Plc 73 5.1.4 Stem Cell Medicine Ltd 77 5.1.5 Tavec Inc. 78 5.1.6 Codiak Biosciences Inc. 80 5.1.7 Therapeutic Solutions International Inc. 81 5.1.8 ArunA Biomedical Inc. 83 5.1.9 Ciloa 85

Read the original here:
2020 Exosome Technologies Market Report- Growth with Capricor, Codiak and Evox Therapeutics among Key Players - 3rd Watch News

Trending: Canine Arthritis Therapeutics Market Research by Key players, Type and Application, Future Growth to 2026 – Cole of Duty

LOS ANGELES, United States: QY Research has recently published a report, titled Global Canine Arthritis Therapeutics Market Size, Status and Forecast 2020-2026.The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Canine Arthritis Therapeutics market. It informs readers about key trends and opportunities in the global Canine Arthritis Therapeutics market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Canine Arthritis Therapeutics market.

Key companies operating in the global Canine Arthritis Therapeutics market include , Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc, Norbrook Laboratories Limited, VetStem Biopharma, Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/customize-request/form/1596595/global-canine-arthritis-therapeutics-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Canine Arthritis Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Canine Arthritis Therapeutics Market Segment By Type:

, Non-Steroidal Anti-Inflammatory Drugs, Opioids, Stem Cell Therapy Canine Arthritis Therapeutics

Global Canine Arthritis Therapeutics Market Segment By Application:

, Veterinary Hospitals and Clinics, Retail Pharmacies, Drug Stores

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Canine Arthritis Therapeutics market.

Key companies operating in the global Canine Arthritis Therapeutics market include , Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc, Norbrook Laboratories Limited, VetStem Biopharma, Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1596595/global-canine-arthritis-therapeutics-market

TOC

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Canine Arthritis Therapeutics Revenue 1.4 Market Analysis by Type 1.4.1 Global Canine Arthritis Therapeutics Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Non-Steroidal Anti-Inflammatory Drugs 1.4.3 Opioids 1.4.4 Stem Cell Therapy 1.5 Market by Application 1.5.1 Global Canine Arthritis Therapeutics Market Share by Application: 2020 VS 2026 1.5.2 Veterinary Hospitals and Clinics 1.5.3 Retail Pharmacies 1.5.4 Drug Stores 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 Canine Arthritis Therapeutics Market Perspective (2015-2026) 2.2 Canine Arthritis Therapeutics Growth Trends by Regions 2.2.1 Canine Arthritis Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Canine Arthritis Therapeutics Historic Market Share by Regions (2015-2020) 2.2.3 Canine Arthritis Therapeutics Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Canine Arthritis Therapeutics Market Growth Strategy 2.3.6 Primary Interviews with Key Canine Arthritis Therapeutics Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Canine Arthritis Therapeutics Players by Market Size 3.1.1 Global Top Canine Arthritis Therapeutics Players by Revenue (2015-2020) 3.1.2 Global Canine Arthritis Therapeutics Revenue Market Share by Players (2015-2020) 3.1.3 Global Canine Arthritis Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Canine Arthritis Therapeutics Market Concentration Ratio 3.2.1 Global Canine Arthritis Therapeutics Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Canine Arthritis Therapeutics Revenue in 2019 3.3 Canine Arthritis Therapeutics Key Players Head office and Area Served 3.4 Key Players Canine Arthritis Therapeutics Product Solution and Service 3.5 Date of Enter into Canine Arthritis Therapeutics Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Canine Arthritis Therapeutics Historic Market Size by Type (2015-2020) 4.2 Global Canine Arthritis Therapeutics Forecasted Market Size by Type (2021-2026) 5 Canine Arthritis Therapeutics Breakdown Data by Application (2015-2026) 5.1 Global Canine Arthritis Therapeutics Market Size by Application (2015-2020) 5.2 Global Canine Arthritis Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Canine Arthritis Therapeutics Market Size (2015-2020) 6.2 Canine Arthritis Therapeutics Key Players in North America (2019-2020) 6.3 North America Canine Arthritis Therapeutics Market Size by Type (2015-2020) 6.4 North America Canine Arthritis Therapeutics Market Size by Application (2015-2020) 7 Europe 7.1 Europe Canine Arthritis Therapeutics Market Size (2015-2020) 7.2 Canine Arthritis Therapeutics Key Players in Europe (2019-2020) 7.3 Europe Canine Arthritis Therapeutics Market Size by Type (2015-2020) 7.4 Europe Canine Arthritis Therapeutics Market Size by Application (2015-2020) 8 China 8.1 China Canine Arthritis Therapeutics Market Size (2015-2020) 8.2 Canine Arthritis Therapeutics Key Players in China (2019-2020) 8.3 China Canine Arthritis Therapeutics Market Size by Type (2015-2020) 8.4 China Canine Arthritis Therapeutics Market Size by Application (2015-2020) 9 Japan 9.1 Japan Canine Arthritis Therapeutics Market Size (2015-2020) 9.2 Canine Arthritis Therapeutics Key Players in Japan (2019-2020) 9.3 Japan Canine Arthritis Therapeutics Market Size by Type (2015-2020) 9.4 Japan Canine Arthritis Therapeutics Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Canine Arthritis Therapeutics Market Size (2015-2020) 10.2 Canine Arthritis Therapeutics Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Canine Arthritis Therapeutics Market Size by Type (2015-2020) 10.4 Southeast Asia Canine Arthritis Therapeutics Market Size by Application (2015-2020) 11 India 11.1 India Canine Arthritis Therapeutics Market Size (2015-2020) 11.2 Canine Arthritis Therapeutics Key Players in India (2019-2020) 11.3 India Canine Arthritis Therapeutics Market Size by Type (2015-2020) 11.4 India Canine Arthritis Therapeutics Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Canine Arthritis Therapeutics Market Size (2015-2020) 12.2 Canine Arthritis Therapeutics Key Players in Central & South America (2019-2020) 12.3 Central & South America Canine Arthritis Therapeutics Market Size by Type (2015-2020) 12.4 Central & South America Canine Arthritis Therapeutics Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Elanco (Eli Lilly and Company) 13.1.1 Elanco (Eli Lilly and Company) Company Details 13.1.2 Elanco (Eli Lilly and Company) Business Overview and Its Total Revenue 13.1.3 Elanco (Eli Lilly and Company) Canine Arthritis Therapeutics Introduction 13.1.4 Elanco (Eli Lilly and Company) Revenue in Canine Arthritis Therapeutics Business (2015-2020)) 13.1.5 Elanco (Eli Lilly and Company) Recent Development 13.2 Boehringer Ingelheim 13.2.1 Boehringer Ingelheim Company Details 13.2.2 Boehringer Ingelheim Business Overview and Its Total Revenue 13.2.3 Boehringer Ingelheim Canine Arthritis Therapeutics Introduction 13.2.4 Boehringer Ingelheim Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.2.5 Boehringer Ingelheim Recent Development 13.3 Zoetis Inc 13.3.1 Zoetis Inc Company Details 13.3.2 Zoetis Inc Business Overview and Its Total Revenue 13.3.3 Zoetis Inc Canine Arthritis Therapeutics Introduction 13.3.4 Zoetis Inc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.3.5 Zoetis Inc Recent Development 13.4 Vetoquinol S.A. 13.4.1 Vetoquinol S.A. Company Details 13.4.2 Vetoquinol S.A. Business Overview and Its Total Revenue 13.4.3 Vetoquinol S.A. Canine Arthritis Therapeutics Introduction 13.4.4 Vetoquinol S.A. Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.4.5 Vetoquinol S.A. Recent Development 13.5 Bayer AG 13.5.1 Bayer AG Company Details 13.5.2 Bayer AG Business Overview and Its Total Revenue 13.5.3 Bayer AG Canine Arthritis Therapeutics Introduction 13.5.4 Bayer AG Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.5.5 Bayer AG Recent Development 13.6 Aratana Therapeutics Inc 13.6.1 Aratana Therapeutics Inc Company Details 13.6.2 Aratana Therapeutics Inc Business Overview and Its Total Revenue 13.6.3 Aratana Therapeutics Inc Canine Arthritis Therapeutics Introduction 13.6.4 Aratana Therapeutics Inc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.6.5 Aratana Therapeutics Inc Recent Development 13.7 Norbrook Laboratories Limited 13.7.1 Norbrook Laboratories Limited Company Details 13.7.2 Norbrook Laboratories Limited Business Overview and Its Total Revenue 13.7.3 Norbrook Laboratories Limited Canine Arthritis Therapeutics Introduction 13.7.4 Norbrook Laboratories Limited Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.7.5 Norbrook Laboratories Limited Recent Development 13.8 VetStem Biopharma 13.8.1 VetStem Biopharma Company Details 13.8.2 VetStem Biopharma Business Overview and Its Total Revenue 13.8.3 VetStem Biopharma Canine Arthritis Therapeutics Introduction 13.8.4 VetStem Biopharma Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.8.5 VetStem Biopharma Recent Development 13.9 Dechra Pharmaceuticals Plc 13.9.1 Dechra Pharmaceuticals Plc Company Details 13.9.2 Dechra Pharmaceuticals Plc Business Overview and Its Total Revenue 13.9.3 Dechra Pharmaceuticals Plc Canine Arthritis Therapeutics Introduction 13.9.4 Dechra Pharmaceuticals Plc Revenue in Canine Arthritis Therapeutics Business (2015-2020) 13.9.5 Dechra Pharmaceuticals Plc Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Excerpt from:
Trending: Canine Arthritis Therapeutics Market Research by Key players, Type and Application, Future Growth to 2026 - Cole of Duty